Image alt Bayer Logo Bayer Logo Bayer Logo Bayer Logo

Patient-centric care

Suspending treatment of nAMD in cases of futility

There is currently no clear consensus on how patients with neovascular age-related macular degeneration (nAMD) who respond poorly to anti-vascular endothelial growth factor (VEGF) therapy should be managed. Suboptimal responses to anti-VEGF may be a result of undertreatment or misdiagnosis of the underlying condition, as well as factors that may preclude continued treatment such as injection or drug-related complications.

 

A recently published Vision Academy review article in Retina introduces an algorithm to guide the management of nAMD in patients with poor response to anti-VEGF treatment. It also provides expert recommendations regarding the suspension of treatment in cases of futility, providing criteria for determining response to anti-VEGF treatment in clinical practice and identifying key factors to be explored when deciding to suspend anti-VEGF treatment.

 

In the video, Dr. David Wong describes the pressing need for expert guidance on switching or suspending treatment in patients with nAMD and suboptimal response to anti-VEGF.

 

 

Read the Vision Academy publication on the futility of treatment in nAMD Read the Vision Academy Viewpoint on the futility of treatment in nAMD

Suspending treatment of nAMD in cases of futility

There is currently no clear consensus on how patients with neovascular age-related macular degeneration (nAMD) who respond poorly to anti-vascular endothelial growth factor (VEGF) therapy should be managed. Suboptimal responses to anti-VEGF may be a result of undertreatment or misdiagnosis of the underlying condition, as well as factors that may preclude continued treatment such as injection or drug-related complications.

 

A recently published Vision Academy review article in Retina introduces an algorithm to guide the management of nAMD in patients with poor response to anti-VEGF treatment. It also provides expert recommendations regarding the suspension of treatment in cases of futility, providing criteria for determining response to anti-VEGF treatment in clinical practice and identifying key factors to be explored when deciding to suspend anti-VEGF treatment.

 

In the video, Dr. David Wong describes the pressing need for expert guidance on switching or suspending treatment in patients with nAMD and suboptimal response to anti-VEGF.

 

 

Read the Vision Academy publication on the futility of treatment in nAMD Read the Vision Academy Viewpoint on the futility of treatment in nAMD

Suspending treatment of nAMD in cases of futility

There is currently no clear consensus on how patients with neovascular age-related macular degeneration (nAMD) who respond poorly to anti-vascular endothelial growth factor (VEGF) therapy should be managed. Suboptimal responses to anti-VEGF may be a result of undertreatment or misdiagnosis of the underlying condition, as well as factors that may preclude continued treatment such as injection or drug-related complications.

 

A recently published Vision Academy review article in Retina introduces an algorithm to guide the management of nAMD in patients with poor response to anti-VEGF treatment. It also provides expert recommendations regarding the suspension of treatment in cases of futility, providing criteria for determining response to anti-VEGF treatment in clinical practice and identifying key factors to be explored when deciding to suspend anti-VEGF treatment.

 

In the video, Dr. David Wong describes the pressing need for expert guidance on switching or suspending treatment in patients with nAMD and suboptimal response to anti-VEGF.

 

 

Read the Vision Academy publication on the futility of treatment in nAMD Read the Vision Academy Viewpoint on the futility of treatment in nAMD